Biorestorative Therapies (BRTX) Expected to Announce Earnings on Wednesday

Biorestorative Therapies (NASDAQ:BRTX) is expected to be releasing its Q2 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($1.40) per share and revenue of $0.65 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 3:30 PM ET.

Biorestorative Therapies Price Performance

Shares of Biorestorative Therapies stock opened at $1.48 on Wednesday. The company has a market capitalization of $2.04 million, a P/E ratio of -0.07 and a beta of 0.93. The business has a 50-day moving average of $2.39 and a two-hundred day moving average of $6.25. Biorestorative Therapies has a 1 year low of $1.28 and a 1 year high of $30.17.

Analyst Upgrades and Downgrades

BRTX has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, August 24th. Maxim Group cut Biorestorative Therapies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

About Biorestorative Therapies

BioRestorative Therapies, Inc is a biotechnology company focused on developing regenerative medicine products using cell and tissue-based technologies. The company’s programs are intended to address conditions for which existing treatment options may be limited, including musculoskeletal and metabolic disorders.

Its lead product candidate, BRTX-100, is an autologous cell therapy developed from a patient’s own bone marrow and designed to treat painful lumbar disc disease, including chronic lower-back pain associated with degenerated discs.